PT-141 (Bremelanotide) for Women: Libido, Safety, and What to Know

Of every peptide women routinely research, PT-141 is the only one with a Phase 3 randomized trial behind it and an actual FDA approval to its name. That is unusual enough to be worth stating up front — and it is what makes a careful conversation about PT-141 possible in a way that simply is not possible for most of the rest of the category.

This piece is the careful conversation. What the molecule is, what the trials showed, who it is approved for, what the safety record looks like, how women actually access it in 2026, and where it fits among the other options for low sexual desire.

What PT-141 / Vyleesi is#

PT-141 is a synthetic melanocortin-receptor agonist. Its generic name is bremelanotide. The brand name is Vyleesi, made by Palatin Technologies and approved by the FDA on June 21, 2019.

The approved indication is narrow and specific: hypoactive sexual desire disorder (HSDD) in premenopausal women. That phrasing matters. HSDD is a clinical diagnosis — persistent, distressing, low sexual desire that is not better explained by another medical condition, a medication, or relationship factors. "Premenopausal" excludes women who have gone through menopause; use of bremelanotide in postmenopausal women is off-label.

The unusual thing about PT-141 in this category is that it does not work on hormones, and it does not work on blood flow. Most prior pharmaceutical attempts to address women's sexual desire fell into one of those two camps — testosterone-adjacent or sildenafil-adjacent — and most underperformed. PT-141 does something different. It acts in the brain.

How it works#

Melanocortin receptors are a family of G-protein-coupled receptors expressed throughout the central nervous system. PT-141 is an agonist (an activator) at several of them, with particular relevance at the MC3R and MC4R receptors. These sit in regions of the hypothalamus and limbic system implicated in sexual motivation, arousal, and reward signaling.

What that means in plain terms: PT-141 is centrally acting. It modulates the brain circuits that produce desire, rather than addressing peripheral symptoms downstream of desire. Animal studies established the mechanism in the late 1990s and early 2000s. Human studies — which took roughly fifteen years to mature — eventually confirmed the same signal in women.

This mechanism also explains the side-effect profile, which appears further down. Activating melanocortin receptors does several things in the body besides influencing sexual response — most notably, increasing nausea pathways, raising blood pressure transiently, and activating skin pigment cells. The PT-141 side-effect list is the price of the mechanism, not an accident of formulation.

What the Phase 3 trials showed#

The basis of FDA approval was a pair of pivotal trials known collectively as RECONNECT (the names are RECONNECT-1 and RECONNECT-2), published in Obstetrics & Gynecology in 2019. Together they enrolled roughly 1,247 premenopausal women with HSDD across the United States. Half received bremelanotide; half received placebo, both self-administered subcutaneously on an as-desired basis.

Two primary endpoints, both standard validated scales in this field:

• FSFI-D (Female Sexual Function Index Desire Domain) — measures sexual desire over the past four weeks.
• FSDS-DAO Item 13 — measures distress related to low desire.

On both endpoints, bremelanotide significantly outperformed placebo. The effect sizes were statistically significant but modest in absolute terms. Roughly one in four women on bremelanotide reported a clinically meaningful response, versus roughly one in six on placebo. That is real, and it is also worth being calibrated about. PT-141 helps a subset of women materially. It does not help everyone. The placebo response in this trial population was substantial.

A trustworthy provider will frame the PT-141 conversation around this distribution: "Some women respond; many do not; we will not know which group you are in until we try, and the answer will be evident within the first one or two doses." A provider who promises a guaranteed response is overstating the data.

Premenopausal vs. postmenopausal use#

This is where most of the confusion in the consumer market currently lives.

The FDA label says premenopausal. The RECONNECT trials enrolled premenopausal women only. Whether PT-141 works comparably in postmenopausal women — and whether its side-effect and cardiovascular profile is acceptable in an older population that more commonly carries cardiovascular risk factors — has not been answered by the same caliber of evidence.

There is some smaller-scale clinical work in postmenopausal women suggesting the mechanism may still produce some benefit, but it is preliminary. Importantly, the cardiovascular cautions on the label apply at least as strongly to postmenopausal women, who as a group carry higher baseline cardiovascular risk.

In practice, telehealth providers routinely prescribe PT-141 off-label to postmenopausal women. That is legal — off-label prescribing is a standard physician prerogative — but it is not what the FDA approval describes, and a careful provider will tell you so out loud. If your provider does not draw this distinction, that is information about how rigorous they are.

Safety profile and side effects#

The PT-141 side-effect list is the most common reason women discontinue, well above lack-of-response.

Common, in clinical trials:

• Nausea is the headline side effect. About 40% of treated women experienced nausea at some point — and nausea was the most common reason women discontinued the drug in trials, with overall discontinuation due to any adverse event running roughly 18% in the bremelanotide arms versus 2% in placebo. The nausea tends to peak in the first hour or two after dosing and tends to attenuate with subsequent doses for many women — but not all.
• Flushing of the face, neck, and chest: about 20%.
• Headache: about 13%.
• Injection-site reactions: about 13%, usually mild redness or tenderness that resolves quickly.

Less common but notable:

• Focal hyperpigmentation: about 1% in trials. Small patches of darker skin, most often on the face, breasts, or gums, that may not fully reverse after stopping the drug. Darker-complexioned women may be at higher risk per the mechanism.
• Transient cardiovascular effects: average systolic blood pressure rise of roughly 6 mmHg and heart-rate decrease of roughly 5 beats per minute, peaking around two to four hours after dose. For most women with normal cardiovascular health, this is clinically irrelevant. For women with uncontrolled hypertension or known cardiovascular disease, the label specifically advises against use.

Contraindications and cautions worth knowing:

• Uncontrolled hypertension.
• Known cardiovascular disease.
• Concurrent use of naltrexone — bremelanotide reduces naltrexone exposure, which is a real problem for women using naltrexone for alcohol use disorder.
• Pregnancy and breastfeeding — not studied; not recommended.
• A daily-dose limit of one injection and a monthly-dose limit of eight injections, per the label.

A reasonable filtering question for a first consult: does this provider take a real medical history before prescribing, including a recent blood-pressure reading? If the answer is no, you are not looking at a careful provider — and the cardiovascular cautions on this drug are not optional.

How women access PT-141#

Two pathways exist in 2026, and they look meaningfully different.

Brand-name Vyleesi. Sold as a single-use auto-injector, prefilled with the standard 1.75 mg dose. Available through retail pharmacies on prescription. Retail cost without insurance is typically several hundred dollars per month at the typical-use cadence; insurance coverage for HSDD treatments is uneven and frequently absent. Vyleesi is the form the FDA actually approved — same molecule, exact specified manufacturing process, identical to what was studied in the trials.

Compounded bremelanotide. Bremelanotide can be prepared by 503A or 503B compounding pharmacies with a prescription. The active ingredient is the same; the form is typically a multi-dose vial drawn into a small subcutaneous syringe rather than a prefilled auto-injector. Cost is substantially lower — usually a fraction of branded retail.

The compounded pathway is where most telehealth providers currently land, and it is also where most of the variability in quality lives. The key questions to ask your provider in either case:

• Which compounding pharmacy? PCAB-accredited is the bar to look for.
• Is a certificate of analysis available for the lot you'll receive?
• What dose protocol are they prescribing, and does it match the FDA-approved dosing of 1.75 mg subcutaneous, as-desired, 45 minutes before activity, capped at eight doses per month?

Any deviation from those parameters is not necessarily wrong, but it should be explained to you, not assumed.

PT-141 vs. other approaches to low desire#

For premenopausal women with HSDD, the FDA-approved pharmacological options are short:

• Flibanserin (Addyi) — a daily oral medication, approved 2015. Works on serotonin and dopamine receptors. Effect size in trials was also modest. Notable interaction with alcohol — the original REMS-program requirement was lifted in 2019, though the alcohol-interaction warning remains on the label. Daily-dosing model means it builds in your system; PT-141's on-demand model is closer to how Viagra is used by men.
• Bremelanotide (Vyleesi) — the drug this piece is about. On-demand, subcutaneous, 45 minutes before activity.

That is the entire FDA-approved list for premenopausal HSDD. Notice what is not on it: testosterone is not FDA-approved for HSDD in women in the United States (it is approved in some other countries for postmenopausal women specifically). Testosterone is widely prescribed off-label by providers who specialize in midlife women's health, with reasonable but limited evidence in postmenopausal women and far less evidence in premenopausal women. Whether testosterone or PT-141 is the right starting point for a given woman is genuinely a conversation with a provider, not a comparison spreadsheet.

For women whose low desire is secondary to something else — antidepressant side effects, untreated depression, vaginal pain, relationship factors, sleep deprivation, perimenopausal hormonal volatility — PT-141 is not the first answer. Addressing the upstream cause is the first answer, and any provider who jumps to PT-141 without ruling that out is selling a drug, not treating a person.

Where this lands#

The reason PT-141 occupies an unusual position in the peptide conversation is that it is the one peptide where a woman can have a fully informed, evidence-grounded discussion with her doctor. The data exists. The label is clear. The trial population is documented. The side-effect profile is characterized. None of that is true to the same degree for BPC-157, TB-500, CJC-1295, or most of the other peptides currently in circulation.

That does not mean it is right for everyone. About a quarter of treated women in the trials reported meaningful benefit. About 40% reported nausea. The cardiovascular cautions are real. The cost — in either pathway — is non-trivial.

It does mean, however, that the conversation about PT-141 can be honest, and so the choice can be informed. Bring the questions in our first-consult checklist to the appointment, listen for the answers, and decide from there.

The peptide is real. The approval is real. The trial data is real. The side-effect profile is also real. All four of those statements need to be sitting on the table at the same time. That is the only honest version of this conversation.